The relationship between body mass index and survival in patients with renal cell carcinoma treated with nivolumab
BMI was an independent prognostic factor in the patients with mRCC treated with nivolumab. Prospective and multicenter research is needed to confirm our findings.
Authors
- Mesut Yılmaz (ORCID: https://orcid.org/0000-0003-1466-3887)
- İlkay Gültürk (ORCID: https://orcid.org/0000-0003-1998-3150)
- Goncagül Akdağ (ORCID: https://orcid.org/0000-0002-6221-0623)
- Sedat Yıldırım (ORCID: https://orcid.org/0000-0002-2423-6902)
- Rumeysa Çolak (ORCID: https://orcid.org/0000-0002-3867-0793)
- Gülhan Dinç (ORCID: https://orcid.org/0009-0007-6025-7800)
- Deniz Tural (ORCID: https://orcid.org/0000-0003-2144-6469)
Institutions
- Koç University (TR)
- Dr Lütfi Kırdar Kartal Eğitim ve Araştırma Hastanesi (TR)
- Bakırköy Dr.Sadi Konuk Eğitim ve Araştırma Hastanesi (TR)
- Sağlık Bilimleri Üniversitesi (TR)
Publication Details
- Journal
- Journal of Chemotherapy
- Published
- 2025-02-23
- DOI
- https://doi.org/10.1080/1120009x.2025.2469371
- Citations
- 1
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.52